Kymera Therapeutics Files Form 4 for 16k Director Stock Option Grant

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) filed a Form 4 on 26 June 2025 disclosing a single equity transaction for director Gorjan Hrustanovic. The filing reports the grant of a stock option covering 16,000 common shares with an exercise price of $46.47 per share.

The option was issued on 25 June 2025 and carries a ten-year term, expiring 24 June 2035. Vesting occurs in full on the earlier of (i) 25 June 2026 or (ii) the date of Kymera’s next annual shareholders’ meeting. No common shares were bought or sold in the open market; the transaction is classified as an "A" (grant) under SEC codes.

The reporting person is a member of BVF Partners L.P. and has agreed to transfer any economic benefit from the option to BVF; consequently, beneficial ownership is disclaimed beyond any pecuniary interest. Following the grant, Hrustanovic holds 16,000 derivative securities directly and reports no change in underlying common-stock ownership.

For investors, this appears to be a routine director compensation grant rather than a signal of changing sentiment or material corporate development. No immediate impact on Kymera’s capitalization, earnings outlook, or governance profile is indicated.

Insights

Financial Analyst

TL;DR: Routine Form 4 shows 16k option grant; neutral, minimal investor impact.

The filing documents a standard non-cash compensation award to director Gorjan Hrustanovic—16,000 options at $46.47, vesting within one year or at the next AGM. The strike is roughly aligned with recent trading levels, offering incentive alignment but no immediate dilution because the options are unexercised. Beneficial ownership is effectively transferred to BVF Partners, so the grant does not reflect direct insider accumulation or disposal of KYMR shares. There are no accompanying share purchases, sales, or managerial departures. Consequently, the disclosure is not impactful for valuation models or near-term share-price dynamics and should be viewed as routine governance housekeeping.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hrustanovic Gorjan

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.47	06/25/2025		A		16,000		(1)	06/24/2035	Common Stock	16,000	$0	16,000	D(2)

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.

2. The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider reported in Kymera Therapeutics (KYMR) latest Form 4?

Gorjan Hrustanovic, a director of Kymera Therapeutics, is the sole reporting person.

What type and size of transaction was disclosed for KYMR?

A grant of 16,000 stock options with no common-stock purchase or sale.

What is the exercise price and term of the options granted to the KYMR director?

The exercise price is $46.47; the options expire on 24 June 2035.

When do the newly granted KYMR options vest?

The options vest in full on the earlier of 25 June 2026 or the next annual shareholders’ meeting.

Does the filing indicate any change in direct share ownership by the insider?

No. After the transaction, Hrustanovic reports 16,000 derivative securities and no change in common-stock holdings.